Is Sermorelin Safe? Side Effects, Monitoring and Who Should Avoid It

Sermorelin is a 29-amino-acid analog of growth-hormone-releasing hormone, the signal your hypothalamus sends to your pituitary; the 1999 BioDrugs review describes it as the shortest synthetic fragment of GHRH with full biological activity. It binds the GHRH receptor on pituitary somatotrophs and prompts a pulse of your own growth hormone. In the 1997 Journal of Clinical Endocrinology and Metabolism trial in age-advanced adults, a nightly injection released growth hormone within about ten minutes for around two hours, after which levels fell back. That is what a pulse looks like.

Supplied growth hormone bypasses your regulation entirely and can push levels well past physiological range. A GHRH analog asks a gland to do what it already does, and somatostatin and IGF-1 feedback still apply: a lower ceiling, a pulsatile rather than flat profile, and a smaller chance of the dose-related problems of growth hormone excess. The 2018 Sexual Medicine Reviews paper on growth hormone secretagogues makes exactly this point: pulsatile release subject to negative feedback can prevent supra-therapeutic growth hormone levels and their consequences.

Feedback limits how high growth hormone can go. It does not stop a dose from being higher than you need within the physiological range, and it does not change what growth hormone does once released. Fluid retention, joint ache and reduced insulin sensitivity are effects of growth hormone, whatever prompted it. See peptides vs HGH.

Released growth hormone acts largely through IGF-1 made in the liver, which is why IGF-1 is the number a physician tracks rather than growth hormone itself. Growth hormone is pulsatile and a single draw tells you almost nothing; IGF-1 integrates output over days, and it is the marker every trial below used to confirm the drug was working and had not overshot.

Sermorelin acetate was marketed as Geref. The FDA approved the diagnostic form, 0.05 mg per ampule, on 28 December 1990 under NDA 19-863, and the treatment form, 0.5 mg and 1.0 mg vials, on 26 September 1997 under NDA 20-443, both held by EMD Serono. The treatment product was indicated for idiopathic growth hormone deficiency in children with growth failure; the diagnostic product for evaluating the pituitary's ability to secrete growth hormone. Approval required safety data submitted to the FDA, which is the foundation of the record and something most compounded peptides lack.

The Geref International Study Group trial, in the Journal of Clinical Endocrinology and Metabolism in 1996, treated 110 previously untreated prepubertal children with growth hormone deficiency for up to a year with a once-daily bedtime injection. The investigators reported no adverse changes in biochemical or hormonal measures, no change in fasting glucose, no excessive generation of IGF-1, and that the drug was well tolerated. The 1999 BioDrugs review reports that single intravenous doses and repeated once-daily subcutaneous doses were well tolerated, with transient facial flushing and injection-site pain the most commonly reported adverse events. The diagnostic use, a single intravenous dose to test pituitary reserve, ran for years in hospital settings where reactions would have been recorded.

This is the evidence that speaks most directly to adult use. In the 1992 Journal of Clinical Endocrinology and Metabolism study from the National Institute on Aging, ten healthy older men took GHRH(1-29) twice daily for fourteen days at each of two doses. Treatment did not affect fasting glucose, urinary C-peptide, blood pressure, or chemistry and hematology profiles; IGF-1 rose into the young-adult range only at the higher dose.

In the 1997 Metabolism study from Johns Hopkins, eleven healthy men aged 64 to 76 with low baseline IGF-1 self-injected GHRH(1-29) nightly for six weeks at home. Nocturnal growth hormone release increased, IGF-1 did not, and no significant adverse effects were observed; weight, body composition, glucose, insulin and lipids were unchanged.

The 1997 Journal of Clinical Endocrinology and Metabolism trial from UC San Diego is the most detailed. Ten women and nine men aged 55 to 71 self-injected placebo nightly for four weeks, then a norleucine-substituted GHRH(1-29) analog nightly for sixteen weeks, randomized and placebo-controlled. IGF-1 and IGFBP-3 rose within two weeks, stayed elevated for twelve, then drifted toward baseline by sixteen. Skin thickness increased in both sexes and lean body mass in men; fasting insulin and glucose were unaltered, and insulin sensitivity rose in men. Blood pressure and weight did not change. The only adverse effect recorded was a transient lipid rise that resolved by the end of the study. A companion paper in the same journal that year, from the same nineteen participants, reported no adverse effects.

The 2006 Neurobiology of Aging trial from the University of Washington gave 89 healthy older adults daily GHRH or placebo for six months and reported improved scores on several cognitive tests. The follow-up in Archives of Neurology in 2012 randomized 152 adults aged 55 to 87, 66 with mild cognitive impairment, to twenty weeks of daily bedtime tesamorelin, a stabilized GHRH analog in the same class, or placebo. IGF-1 rose by 117 percent but stayed within the physiological range; fasting insulin rose 35 percent, within normal range, in the mild-cognitive-impairment group only; adverse events were mild, reported by 68 percent on treatment versus 36 percent on placebo. That trial used tesamorelin, not sermorelin, and is included because the two act on the same receptor.

The 2003 review in Endocrine from the Washington group concluded that GHRH and secretagogues elevate IGF-1 to younger-adult ranges, that several months of GHRH increases lean mass, that a short-acting GHRH did not improve sleep, and that the results, while encouraging, did not yet support routine use in normal aging. The 2018 Sexual Medicine Reviews paper reached a similar position: well tolerated in available studies, some concern about blood glucose through reduced insulin sensitivity, and a need for long-term data including cancer incidence. The 2006 Clinical Interventions in Aging commentary argued for sermorelin over supplied growth hormone in adult-onset insufficiency on the feedback grounds above.

No trial has followed adults using sermorelin for wellness goals over years; the longest placebo-controlled adult exposure is about six months. There is no human dose-ranging study behind adult schedules and no head-to-head safety trial against CJC-1295, ipamorelin or tesamorelin. These gaps are why monitoring is not optional.

Injection-site reactions are the most consistently reported effect across the pediatric program and the adult trials: redness, itching and a small firm lump that resolves over a day or two. Rotating sites and letting the vial reach room temperature before drawing reduce it. A reaction that spreads, blisters or persists beyond a few days is not typical and should be reported. Transient facial flushing was, with injection-site pain, the most common adverse event in the pediatric review; it arrives within minutes, passes within the hour, and is vascular rather than allergic. Headache in the first weeks is reported by a minority and is usually mild; a severe or persistent headache, or one with vision change, is outside the expected pattern and warrants same-day contact.

Sermorelin is usually taken at bedtime because the largest natural growth hormone pulse occurs in the first hours of sleep, and some people report more vivid dreams in the first weeks. Patients commonly describe sleep feeling deeper; the 2003 Endocrine review notes that a short-acting GHRH did not improve measured sleep under trial conditions, so treat sleep effects as reported rather than demonstrated. Moving the injection earlier in the evening is the usual adjustment.

Growth hormone promotes sodium and water retention and soft-tissue swelling. At a dose above what your body needs, that shows up as puffy ankles or fingers, stiffness on waking, aching joints, and tingling or numbness in the hands from pressure on the median nerve at the wrist. This cluster is the recognized signature of growth hormone excess in the supplied-hormone literature, and the reason the 1997 UC San Diego investigators noted that adverse effects had limited the usefulness of recombinant growth hormone in older adults. With sermorelin it is uncommon, because feedback caps the release, but not impossible. It is a dose message; the response is a lower dose or a changed schedule, decided by your prescriber.

Sermorelin on its own is not usually associated with appetite change. The Ipamorelin + Sermorelin pairing adds a ghrelin-receptor agonist; ghrelin is the hunger hormone, and although the 1998 European Journal of Endocrinology paper characterizing ipamorelin describes it as selective for growth hormone release, some people report more appetite on the combination. Report it if it interferes with a weight goal. Separately, any injected peptide can provoke hypersensitivity; true allergy to sermorelin is rare. Facial or throat swelling, hives spreading beyond the injection site, or any breathing difficulty is an emergency first and a message to your prescriber second.

Growth hormone and IGF-1 are growth signals. No study has shown that sermorelin causes cancer in humans, and the 2018 review states that long-term cancer-incidence data for the secretagogue class do not exist; the observational literature linking naturally high IGF-1 to some cancers concerns lifelong levels, not a medication run at physiological doses under monitoring. The caution is precautionary: a physician does not add a growth signal to a body with active abnormal cell growth. Active malignancy is a decline. A history in remission is a conversation, usually involving the oncologist, that depends on the cancer, the time since treatment and the surveillance in place.

Growth hormone raises blood glucose by reducing tissue sensitivity to insulin. In the trials above this did not become a problem: fasting glucose was unchanged in the pediatric trial, the 1992 study, the 1997 Johns Hopkins study and the 1997 UC San Diego study, and insulin sensitivity rose in men in the last of those. The 2012 tesamorelin trial did see fasting insulin rise, within normal range, in the mild-cognitive-impairment group. So the effect is real, small at physiological doses, and larger in people whose glucose handling is already strained. Diabetes and prediabetes are not automatic declines, but they put glucose and HbA1c into the baseline and follow-up panels and lower the threshold for a dose review. Active proliferative diabetic retinopathy is a firm decline, because growth hormone and IGF-1 have a role in retinal blood-vessel growth.

Untreated obstructive sleep apnea is a caution because fluid retention and soft-tissue swelling in the upper airway can worsen it; someone on effective CPAP is in a different position from someone with loud snoring and daytime sleepiness who has never been assessed. Thyroid matters for two reasons: growth hormone can increase conversion of T4 to T3 and unmask marginal hypothyroidism, and untreated hypothyroidism blunts the IGF-1 response, which makes the monitoring uninterpretable. An abnormal baseline thyroid result is treated first.

Not used in pregnancy or breastfeeding: there is no safety data, the trials excluded these groups, and there is no clinical reason to accept the uncertainty. Sermorelin was approved for children with diagnosed growth hormone deficiency under specialist care with bone-age monitoring; that is a pediatric endocrinology decision, and Pepti prescribes to adults only.

Not normally. The pediatric investigators reported no excessive IGF-1 generation; the 2012 trial saw a large percentage rise that stayed within physiological range; the 1997 UC San Diego trial saw IGF-1 drift back toward baseline by sixteen weeks despite continued dosing. Overshoot is possible with an unusually high dose, which is why a repeat IGF-1 is drawn after the first weeks.

The 1997 UC San Diego trial reported that the growth hormone-releasing effect was sustained through sixteen weeks of nightly dosing, even as IGF-1 settled. The pediatric review describes growth responses sustained through twelve months, with data in a few children suggesting effect maintained at 36 months. Desensitization has been a concern with some ghrelin-receptor peptides; for the GHRH receptor the available data do not show it over these durations, and beyond a year in adults the question is open. Any injected peptide can also provoke antibodies; the pediatric trial reported no adverse hormonal or biochemical changes across a year, and a neutralizing antibody would show up as an IGF-1 that stops responding, which the monitoring would catch.

There is no formal interaction study for compounded sermorelin; the physiology is what a physician works from. Glucocorticoids suppress growth hormone release and can blunt the response. Insulin and other glucose-lowering medications may need attention because growth hormone shifts insulin sensitivity. Thyroid replacement is relevant for the reasons above. This is why the intake asks for every medication and supplement and a physician rather than a form reviews it.

Sermorelin and ipamorelin act on different receptors, GHRH and ghrelin, and the 1995 Clinical Endocrinology study of a GHRH given with a ghrelin-receptor peptide in adult volunteers reported a larger growth hormone response to the combination than to either alone. That is the rationale for Ipamorelin + Sermorelin and the three-signal CJC-1295 / Ipamorelin / Sermorelin Pen. A larger response means the dose-signal cluster deserves more attention, not less; the monitoring is the same. The 2006 Journal of Clinical Endocrinology and Metabolism work on CJC-1295 in healthy adults reported that growth hormone release stayed pulsatile under continuous stimulation, the same feedback argument applied to the longer-acting analog. See CJC-1295 vs sermorelin.

Tesamorelin, a stabilized GHRH analog with a larger trial base, has the closest thing to a long-exposure dataset for this receptor: mild adverse events, IGF-1 within range, small rises in fasting insulin in susceptible groups. A physician choosing between sermorelin and tesamorelin is choosing on goal and duration of action, not on a safety difference. See what is tesamorelin.

In 2008 EMD Serono notified the FDA that both Geref products were being discontinued and requested withdrawal of the applications, and the FDA withdrew approval of NDA 19-863 and NDA 20-443 effective 18 June 2009. That was a commercial decision by the sponsor, not a regulatory action against the drug. In response to a citizen petition, the FDA reviewed its records and published a determination in the Federal Register on 4 March 2013 that both products were not withdrawn from sale for reasons of safety or effectiveness, a finding that allows the agency to approve generic applications referencing Geref. For a patient the point is simpler: the agency looked at the file and found no safety reason for the product's disappearance, which is the opposite of the position most compounded peptides are in, where there was never an approved product to review.

Sermorelin does not appear in any category of the FDA's list of bulk drug substances nominated for use in compounding under section 503A, as updated 14 May 2026: not in Category 1 (under evaluation), not in Category 2 (substances that raise significant safety concerns), and not in Category 3 (nominated without adequate support). The reason it was never nominated is structural: section 503A allows a pharmacy to compound from a bulk substance that was a component of an FDA-approved drug, and sermorelin acetate was the active ingredient of Geref. It does not need the list. By contrast, the ghrelin-receptor peptides GHRP-2 and GHRP-6 sit in Category 3, and ibutamoren is in Category 2, on that same update.

Compounded sermorelin is not an FDA-approved drug product. No compounded medication is; approval attaches to a specific manufactured product, and Geref is no longer marketed. Compounding means a state-licensed pharmacy prepares the medication to a physician's prescription for a named patient, from a bulk ingredient that meets the statutory criteria, and is accountable for identity, purity, sterility and concentration. Pepti publishes lab results at /quality/lab-results. See are peptides FDA approved.

The 2026 WADA Prohibited List, in effect from 1 January 2026, lists growth hormone-releasing hormone and its analogs, naming CJC-1293, CJC-1295, sermorelin and tesamorelin, under S2.2.4, growth hormone releasing factors, prohibited at all times; ipamorelin, ibutamoren and the GHRPs sit in the same section. A tested athlete should not start any of these without a therapeutic use exemption, and should tell the prescribing physician.

A baseline IGF-1 tells the prescriber where you start; the trials selected older adults with low values, and the response is larger from a low starting point. Fasting glucose and, where indicated, HbA1c establish glucose handling before growth hormone shifts it. Lipids are included because the one adverse effect in the sixteen-week UC San Diego trial was a transient lipid rise. Thyroid function is included because an untreated thyroid problem both blunts the response and confuses the picture.

Between weeks four and twelve IGF-1 has risen and settled; the 1997 trial saw it up within two weeks and stable through twelve. A value in the upper part of the age-adjusted reference range is where a prescriber wants it. A value above range is a dose message. A value that has not moved raises questions of technique, storage and thyroid status first.

After the first repeat, IGF-1 and glucose on the schedule your physician sets, typically alongside 28-day refills, with lipids if the baseline was borderline. Treatment is long-term, so this is a rhythm rather than an event. A rising IGF-1 means the pituitary is responding; whether that is good news depends on where the number lands. The trials produced their results with IGF-1 inside the physiological range, and the adverse-effect cluster appears when it is pushed beyond.